Urologix said that Thayne Larson, MD, will present the two abstracts in a podium session. Dr Larson is one of the early participants in clinical trials with Urologix in 1991; he practiced at the Mayo Clinic, Scottsdale, AZ and is an independent researcher at The Institute of Medical Research, Scottsdale, AZ.

Urologix exhibit will emphasise the advantages of Cooled ThermoTherapy versus benign prostatic hyperplasia (BPH) drugs while also demonstrating the distinct difference in peer reviewed published data available to support cooled high-energy transurethral microwave therapy versus low energy alternatives.

Stryker Warren, CEO, said: “We are pleased the Geriatric Urological Society selected ‘Sexual Function after Cooled High Energy Transurethral Thermotherapy: Results of Patient Clinical Data up to 5 Years Post-Treatment’ and ‘Intra-Prostatic Temperatures and Necrosis during High Energy Cooled Microwave Treatment’ for presentation. Urologix has led the minimally invasive space for the treatment of BPH when one inventories the clinical studies and the resultant publications and presentations.

“This speaks to both the efficacy of our technology and our commitment to the science of high energy, cooled microwave therapy. We are gratified by the interest again this year in clinical abstracts which advance the knowledge and the comparative effectiveness of high energy, Cooled ThermoTherapy™ which is the province of Urologix.”

Minneapolis-based Urologix is a developer, manufacturer and marketer of minimally invasive Cooled ThermoTherapy technology to urologists for BPH patients. The company also develops and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of BPH.